A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
In order to evaluate immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine produced by Beijing Minhai Biotechnology Co., Ltd., a randomized, double-blind, parallel-controlled phase III clinical trial is planned to conduct in healthy infants aged 2 months in China.
Epistemonikos ID: aca1f1d6475f36c1e6470f75895d780dd42a79fa
First added on: May 12, 2024